Eye injection for wet amd and related retina conditions
Part of Eyes & vision, Heart & circulation clinical trials.
This trial tests a new eye injection (GenSci148) for people with wet age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. The injection may help reduce swelling and abnormal blood vessel growth in the retina, which can improve or stabilise vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to give written permission to take part (informed consent).
- You need to be able to attend all study visits and follow the treatment plan.
- Your treated eye must have fairly good but not perfect vision (about 20/40 to 20/320).
- Your other eye also needs to see at least at the level of 20/320 or better.
- You cannot have had certain other eye treatments that are not allowed (your doctor will check).
- Your treated eye cannot have very high nearsightedness (more than -8.0 diopters), bleeding in the back of the eye, or certain abnormal blood vessels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
This trial tests a new eye injection called GB10 for people with wet AMD, a condition that causes rapid vision loss. The goal is to see if it is safe and works to improve or stabilize vision.
This trial tests a one-time gene therapy injection into the eye for adults with diabetic macular edema (DME), a condition where fluid builds up in the retina and blurs vision. The goal is to reduce the need for frequent eye injections and help maintain vision over time.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.